CL2013002006A1 - Composicion farmaceutica que comprende un anticuerpo aislado que se une especificamente al factor de celulas madres; metodo de produccion del anticuerpo; y su uso para tratar o prevenir una enfermedad de remodelacion tisular o fibrotica en un sujeto. - Google Patents

Composicion farmaceutica que comprende un anticuerpo aislado que se une especificamente al factor de celulas madres; metodo de produccion del anticuerpo; y su uso para tratar o prevenir una enfermedad de remodelacion tisular o fibrotica en un sujeto.

Info

Publication number: CL2013002006A1
Authority: CL; Chile
Prior art keywords: treat; disease; tissue; subject; pharmaceutical composition
Prior art date: 2011-01-10

Application number

CL2013002006A

Other languages

English (en)

Inventor

Nicholas W Lukacs

Vladislav A Dolgachev

Steven L Kunkel

Cory M Hogaboam

Sem H Phan

Original Assignee

Univ Michigan

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-01-10

Filing date

2013-07-09

Publication date

2014-05-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46507636&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013002006(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-07-09 Application filed by Univ Michigan filed Critical Univ Michigan

2014-05-09 Publication of CL2013002006A1 publication Critical patent/CL2013002006A1/es

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Dermatology (AREA)
Otolaryngology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)

CL2013002006A 2011-01-10 2013-07-09 Composicion farmaceutica que comprende un anticuerpo aislado que se une especificamente al factor de celulas madres; metodo de produccion del anticuerpo; y su uso para tratar o prevenir una enfermedad de remodelacion tisular o fibrotica en un sujeto. CL2013002006A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161431246P	2011-01-10	2011-01-10

Publications (1)

Publication Number	Publication Date
CL2013002006A1 true CL2013002006A1 (es)	2014-05-09

Family

ID=46507636

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013002006A CL2013002006A1 (es)	2011-01-10	2013-07-09	Composicion farmaceutica que comprende un anticuerpo aislado que se une especificamente al factor de celulas madres; metodo de produccion del anticuerpo; y su uso para tratar o prevenir una enfermedad de remodelacion tisular o fibrotica en un sujeto.

Country Status (18)

Country	Link
US (6)	US8911729B2 (es)
EP (1)	EP2663333B8 (es)
JP (3)	JP2014505057A (es)
KR (2)	KR20200023495A (es)
CN (2)	CN103547288B (es)
AU (2)	AU2012205718B2 (es)
BR (1)	BR112013017585A2 (es)
CA (1)	CA2823913C (es)
CL (1)	CL2013002006A1 (es)
DE (1)	DE112012000439T5 (es)
ES (1)	ES2808529T3 (es)
GB (2)	GB2559498B (es)
HK (1)	HK1223375A1 (es)
IL (1)	IL227394A (es)
MX (1)	MX353309B (es)
RU (1)	RU2013131825A (es)
WO (1)	WO2012096960A2 (es)
ZA (1)	ZA201305149B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20200023495A (ko)	2011-01-10	2020-03-04	더 리젠츠 오브 더 유니버시티 오브 미시간	줄기 세포 인자 억제제
KR101384360B1 (ko) *	2012-05-04	2014-04-14	아주대학교산학협력단	Ｓｃｆ 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
WO2015006554A1 (en)	2013-07-10	2015-01-15	The Regents Of The University Of Michigan	Therapeutic antibodies and uses thereof
US20190086392A1 (en)	2016-03-21	2019-03-21	Inserm (Institut National De La Sante Et De La Recherch Medicale)	Methods for diagnosis and treatment of solar lentigo
WO2018085516A2 (en) *	2016-11-02	2018-05-11	Aal Scientifics, Inc.	Non-mesenchymal human lung stem cells and methods of their use for treating respiratory diseases
KR102131898B1 (ko) *	2017-10-31	2020-07-08	주식회사 노벨티노빌리티	Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도
US20220324957A1 (en)	2019-09-16	2022-10-13	Opsidio, LLC	Anti-stem cell factor antibodies and methods of use thereof in renal disease
JP2024511027A (ja) *	2021-03-17	2024-03-12	オプシディオ，エルエルシー	幹細胞因子抗体及びその使用方法
KR20250167153A (ko) *	2023-03-03	2025-11-28	셀덱스 쎄라퓨틱스, 인크.	항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JPS6147500A (ja)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
JPS61134325A (ja)	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de)	1985-11-01	1994-03-03	Xoma Corp	Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
EP0676470A1 (en) *	1989-10-16	1995-10-11	Amgen Inc.	Stem cell factor
HUT62011A (en) *	1989-10-16	1993-03-29	Amgen Inc	Process for producing factors influencing the functioning of stem cells
US7144731B2 (en) *	1989-10-16	2006-12-05	Amgen Inc.	SCF antibody compositions and methods of using the same
US5589582A (en) *	1992-10-27	1996-12-31	Biotransplant, Inc.	Polynucleotides en coding porcine cytokines
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US5885962A (en) *	1996-04-05	1999-03-23	Amgen Inc.	Stem cell factor analog compositions and method
CZ106299A3 (cs)	1996-09-26	1999-08-11	Chugai Seiyaku Kabushiki Kaisha	Protilátky proti proteinu příbuznému s lidským parathyroidálním hormonem
US6506559B1 (en)	1997-12-23	2003-01-14	Carnegie Institute Of Washington	Genetic inhibition by double-stranded RNA
US6989248B2 (en) *	1999-05-06	2006-01-24	The Trustees Of Columbia University In The City Of New York	Methods of use of compounds which inhibit the stem cell signaling pathway
CN100523215C (zh)	2000-12-01	2009-08-05	马普科技促进协会	介导rna干涉的小rna分子
US20100305003A1 (en) *	2001-03-05	2010-12-02	Arca Biopharma Inc.	Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
BR0211111A (pt)	2001-07-12	2004-06-22	Univ Massachusetts	Molécula de ácido nucleico isolada, vetor, célula hospedeira, transgene, precursor de rna engenheirado, animal transgênico não humano, e, método de induzir a interferência de ácido ribonucleico de um gene alvo em uma célula
AR037756A1 (es) *	2001-12-17	2004-12-01	Bayer Corp	Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
JP2005517450A (ja)	2002-02-20	2005-06-16	サーナ・セラピューティクス・インコーポレイテッド	短干渉核酸（ｓｉＮＡ）を用いるＲＮＡ干渉媒介性標的発見および標的評価
WO2004022593A2 (en)	2002-09-09	2004-03-18	Nautilus Biotech	Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
CA2499188A1 (en)	2002-09-27	2004-04-08	Cold Spring Harbor Laboratory	Cell-based rna interference and related methods and compositions
US7582297B2 (en) *	2003-04-11	2009-09-01	Medimmune, Llc	Methods of treating respiratory conditions
WO2005038054A1 (en)	2003-10-20	2005-04-28	Zicai Liang	METHOD OF MEASURING THE EFFICACY OF siRNA MOLECULES
GB0327726D0 (en)	2003-11-28	2003-12-31	Isis Innovation	Method
ES2689328T3 (es)	2004-01-07	2018-11-13	Novartis Vaccines And Diagnostics, Inc.	Anticuerpo monoclonal M-CSF-específico y usos del mismo
US20050282233A1 (en)	2004-03-05	2005-12-22	Ludwig Institute For Cancer Research	Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
GB0521621D0 (en)	2005-10-24	2005-11-30	Domantis Ltd	Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
US20090123426A1 (en)	2004-12-17	2009-05-14	Chiang Li	Compositions for Bacterial Mediated Gene Silencing and Methods of Using the Same
EP2089521A1 (en)	2006-02-08	2009-08-19	Ercole Biotech, Inc.	Soluble tnf receptors and their use in treatment of disease
TWI395754B (zh) *	2006-04-24	2013-05-11	Amgen Inc	人類化之ｃ-ｋｉｔ抗體
US20100062994A1 (en)	2006-07-14	2010-03-11	Santaris Pharma A/S	Adenosine Receptor Antagonists
EP2076597A2 (en)	2006-10-09	2009-07-08	Santaris Pharma A/S	Rna antagonist compounds for the modulation of pcsk9
US7834154B2 (en)	2007-02-09	2010-11-16	Genentech, Inc.	Anti-ROBO4 antibodies and uses therefor
US8236527B2 (en) *	2008-03-14	2012-08-07	Humanzyme Limited	Recombinant production of authentic human proteins using human cell expression systems
WO2009117769A1 (en)	2008-03-25	2009-10-01	Newcastle Innovation Limited	Inhibition of c-kit cancers
WO2011016238A1 (en)	2009-08-06	2011-02-10	Immunas Pharma, Inc.	Antibodies that specifically bind to a beta oligomers and use thereof
KR20200023495A (ko)	2011-01-10	2020-03-04	더 리젠츠 오브 더 유니버시티 오브 미시간	줄기 세포 인자 억제제

2012
- 2012-01-10 KR KR1020207005124A patent/KR20200023495A/ko not_active Ceased
- 2012-01-10 DE DE112012000439.6T patent/DE112012000439T5/de not_active Ceased
- 2012-01-10 WO PCT/US2012/020782 patent/WO2012096960A2/en not_active Ceased
- 2012-01-10 KR KR1020137021010A patent/KR102119187B1/ko active Active
- 2012-01-10 RU RU2013131825/10A patent/RU2013131825A/ru not_active Application Discontinuation
- 2012-01-10 AU AU2012205718A patent/AU2012205718B2/en active Active
- 2012-01-10 US US13/347,459 patent/US8911729B2/en active Active
- 2012-01-10 ES ES12734690T patent/ES2808529T3/es active Active
- 2012-01-10 GB GB1804827.2A patent/GB2559498B/en active Active
- 2012-01-10 MX MX2013008069A patent/MX353309B/es active IP Right Grant
- 2012-01-10 CN CN201280012594.7A patent/CN103547288B/zh active Active
- 2012-01-10 GB GB1312965.5A patent/GB2502462B/en active Active
- 2012-01-10 CA CA2823913A patent/CA2823913C/en active Active
- 2012-01-10 CN CN201610086639.5A patent/CN105646709A/zh active Pending
- 2012-01-10 EP EP12734690.6A patent/EP2663333B8/en active Active
- 2012-01-10 JP JP2013548621A patent/JP2014505057A/ja active Pending
- 2012-01-10 BR BR112013017585-0A patent/BR112013017585A2/pt not_active Application Discontinuation
2013
- 2013-07-09 US US13/937,852 patent/US9353178B2/en active Active
- 2013-07-09 CL CL2013002006A patent/CL2013002006A1/es unknown
- 2013-07-09 IL IL227394A patent/IL227394A/en active IP Right Grant
- 2013-07-09 ZA ZA2013/05149A patent/ZA201305149B/en unknown
2016
- 2016-03-02 US US15/058,918 patent/US9790272B2/en active Active
- 2016-10-03 HK HK16111497.7A patent/HK1223375A1/zh unknown
- 2016-11-11 JP JP2016220281A patent/JP6764318B2/ja not_active Expired - Fee Related
2017
- 2017-10-05 AU AU2017239554A patent/AU2017239554B2/en active Active
- 2017-10-12 US US15/782,503 patent/US20180030129A1/en not_active Abandoned
2018
- 2018-09-06 JP JP2018167097A patent/JP6764447B2/ja active Active
2021
- 2021-10-04 US US17/493,411 patent/US20220017613A1/en not_active Abandoned
2024
- 2024-06-03 US US18/731,458 patent/US20250042986A1/en active Pending

Also Published As

Publication number	Publication date
JP2014505057A (ja)	2014-02-27
KR102119187B1 (ko)	2020-06-08
GB201312965D0 (en)	2013-09-04
AU2017239554A1 (en)	2017-10-26
US20220017613A1 (en)	2022-01-20
JP6764318B2 (ja)	2020-09-30
EP2663333B1 (en)	2020-05-06
US20120321629A1 (en)	2012-12-20
GB2559498A (en)	2018-08-08
EP2663333A4 (en)	2016-01-06
US8911729B2 (en)	2014-12-16
WO2012096960A3 (en)	2012-09-07
EP2663333B8 (en)	2020-06-17
GB2502462A (en)	2013-11-27
BR112013017585A2 (pt)	2020-11-24
JP2019001808A (ja)	2019-01-10
AU2012205718A1 (en)	2013-07-25
MX353309B (es)	2018-01-08
US20180030129A1 (en)	2018-02-01
RU2013131825A (ru)	2015-02-20
CA2823913C (en)	2023-10-03
AU2017239554B2 (en)	2018-11-29
ES2808529T3 (es)	2021-03-01
US20250042986A1 (en)	2025-02-06
NZ702818A (en)	2016-02-26
US9790272B2 (en)	2017-10-17
DE112012000439T5 (de)	2014-04-30
CN103547288B (zh)	2016-03-16
NZ612783A (en)	2014-12-24
HK1223375A1 (zh)	2017-07-28
JP2017061516A (ja)	2017-03-30
GB2502462B (en)	2018-08-08
ZA201305149B (en)	2014-09-25
IL227394A0 (en)	2013-09-30
WO2012096960A2 (en)	2012-07-19
CN105646709A (zh)	2016-06-08
US9353178B2 (en)	2016-05-31
JP6764447B2 (ja)	2020-09-30
EP2663333A2 (en)	2013-11-20
GB201804827D0 (en)	2018-05-09
MX2013008069A (es)	2014-03-21
KR20200023495A (ko)	2020-03-04
HK1192475A1 (zh)	2014-08-22
US20160251423A1 (en)	2016-09-01
CN103547288A (zh)	2014-01-29
US20140023651A1 (en)	2014-01-23
IL227394A (en)	2017-10-31
AU2012205718B2 (en)	2017-07-06
CA2823913A1 (en)	2012-07-19
KR20140056142A (ko)	2014-05-09
GB2559498B (en)	2018-10-24

Publication	Publication Date	Title
BR112013018877A2 (pt)	2016-10-04	composições farmacêuticas que compreendem anticorpos humanos para pcsk9
CL2012000620A1 (es)	2013-09-06	Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
BR112013024574A2 (pt)	2017-09-19	polipeptídeo, uso, método de tratamento de indivíduos portadores de doenças e método de tratamento de indivíduos que possuem doenças com um polipeptídeo
CL2014002750A1 (es)	2015-04-06	Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer
CL2013002811A1 (es)	2014-02-28	Anticuerpo monoclonal aislado que se une a un epitopo del inhibidor de la ruta del factor tisular humano; molecula de acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar deficiencias o defectos geneticos o adquiridos en la coagulacion.
CL2014000183A1 (es)	2014-07-11	Formulación farmacéutica que contienen anticuerpos anti-pcsk9; metodo para preparar dicha formulación.
CL2014001640A1 (es)	2014-12-05	Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo.
AR090903A1 (es)	2014-12-17	Anticuerpos e inmunoconjugados anti-pmel17
PT2704703T (pt)	2019-10-25	Composições transdermais de ibuprofeno e seus métodos de utilização.
PL3489261T3 (pl)	2021-08-16	Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
CO6900118A2 (es)	2014-03-20	Métodos para tratar el cancer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek
GT201400147A (es)	2015-04-06	Pirimidinas y triazinas fusionadas sustituidas y su uso
CO6821893A2 (es)	2013-12-31	Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
CL2014000758A1 (es)	2014-08-22	Anticuerpo aislado o fragmento del mismo que se une especificamente a erbb3; composicion farmaceutica que lo comprende; y su uso para inhibir el crecimiento tumoral.
CL2013000238A1 (es)	2014-03-28	Uso de inhibores de la succinato deshidrogenasa y/o inhibidores del complejo iii para mejorar la relacion entre microorganismos dañinos y beneficiosos.
BR112014010206A2 (pt)	2017-05-16	composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
AR090339A1 (es)	2014-11-05	Metodos de pronostico, diagnostico y tratamiento de la fibrosis pulmonar idiopatica
CL2013000930A1 (es)	2014-03-28	Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17.
CL2014000541A1 (es)	2014-08-22	Citomegalovirus de replicacion defectuosa condicionada; metodo de produccion; composicion que lo comprende; y su uso para tratar una infeccion por citomegalovirus.
CL2013001947A1 (es)	2014-05-23	Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
CR20140279A (es)	2014-08-04	Proteínas que pueden unirse a la il-1
CL2013000801A1 (es)	2013-11-29	Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion
CL2013000455A1 (es)	2013-05-03	Compuestos derivados oxadiazol, inhibidores de la produccion de leucotrienos; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas y cancer.
HUE042008T2 (hu)	2019-06-28	Prosztataspecifikus õssejt antigén elleni antitestek és alkalmazásuk
CL2011000931A1 (es)	2012-03-16	Anticuerpo humanizado anti-alfa2 integrina; uso del anticuerpo antes mencionado para tratar cancer.